



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17223-002001	Application No. 09/998,497
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Paul O.P. Ts'o et al.	
		Filing Date November 30, 2001	Group Art Unit 1623

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>Ho</i>	AA	5,457,187	10/10/1995	Gmeiner et al.	536	25.5	
<i>Ho</i>	AB	5,614,505	3/25/1997	Gmeiner et al.	514	50	
<i>Ho</i>	AC	5,663,321	9/2/1997	Gmeiner et al.	536	25.5	
<i>Ho</i>	AD	5,741,900	4/21/1998	Gmeiner et al.	536	25.31	
<i>Ho</i>	AE	6,342,485	1/29/2002	Gmeiner et al.	514	44	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF							
	AG							
	AH							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>Ho</i>	AI	Desmoulin et al., "Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats..." Xenobiotica 33(3):289-303, 2003.
<i>Ho</i>	AJ	Di Stefano et al., "Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity..." Ital. J. of Gastroenterol Hepatol. 30:173-177, 1998.
<i>Ho</i>	AK	Rohlf et al., "Hepatocyte-activated glycol-conjugated 5-FU prodrug inhibits liver colonies of rat sarcoma" Pharmacology/Therapeutics: Proc. of the American Assoc. for Cancer Res. (abstract) 38:10, 1997.
<i>Ho</i>	AL	Schwartz et al., "Characterization of the Asialoglycoprotein Receptor in a Continuous Hepatoma Line" J. of Biol. Chem. 256(17):8878-8881, 1981.
<i>Ho</i>	AM	Schwartz et al., "Kinetics of Internalization and Recycling of the Asialoglycoprotein Receptor in a Hepatoma Cell Line" J. of Biol. Chem. 257(8):4230-4237, 1982.
<i>Ho</i>	AN	Sharma et al., "Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver" Cancer Chemother. Pharmacol. 48:197-201, 2001.

Examiner Signature <i>David Jones</i>	Date Considered <i>6/25/05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	